Format

Send to

Choose Destination
Bull Cancer. 2014 May 1;101(5):481-5. doi: 10.1684/bdc.2014.1924.

[Quality criteria in radiotherapy for head and neck cancers under the aegis of Head and Neck Intergroup].

[Article in French]

Author information

1
Institut Gustave Roussy, département de radiothérapie, 114 rue Edouard-Vaillant, 94800 Villejuif, France, Groupe d'oncologie radiothérapie tête et cou (GORTEC), Tours, France.
2
Groupe d'oncologie radiothérapie tête et cou (GORTEC), Tours, France.
3
Institut Sainte-Catherine, Avignon, France.
4
Institut de cancérologie de Lorraine Alexis-Vautrin, Nancy, France.
5
Centre hospitalier universitaire de Charleroi, Belgique.
6
Groupe d'oncologie radiothérapie tête et cou (GORTEC), Tours, France, Institut de cancérologie de l'Ouest René-Gauducheau, Nantes, France.
7
Groupe d'oncologie radiothérapie tête et cou (GORTEC), Tours, France, Centre hospitalier universitaire de Lausanne, Suisse.

Abstract

The aim of radiotherapy is to deliver enough radiation to the tumor in order to achieve maximum tumour control in the irradiated volume with as few serious complications as possible with an irradiation dose as low as possible to normal tissue. The quality of radiotherapy is essential for optimal treatment and quality control is to reduce the bias in clinical trials avoiding possible major deviations. The assurance and quality control programs have been developed in large european (EORTC, GORTEC) and american cooperative groups (RTOG) of radiation oncology since the 1980s. We insist here on the importance of quality assurance in radiotherapy and the current status in this domain and the criteria for quality control especially for current clinical trials within GORTEC are discussed here.

KEYWORDS:

cancer; head and neck; quality assurance; quality control; radiotherapy

PMID:
24886899
DOI:
10.1684/bdc.2014.1924
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center